Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Fischer, K; Cramer, P; Busch, R; Stilgenbauer, S; Bahlo, J; Schweighofer, CD; Böttcher, S; Staib, P; Kiehl, M; Eckart, MJ; Kranz, G; Goede, V; Elter, T; Bühler, A; Winkler, D; Kneba, M; Döhner, H; Eichhorst, BF; Hallek, M; Wendtner, CM 
Titel:
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. 
Abstract:
The objective of this trial was to evaluate safety and efficacy of bendamustine combined with rituximab (BR) in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).Seventy-eight patients, including 22 patients with fludarabine-refractory disease (28.2%) and 14 patients (17.9%) with deletion of 17p, received BR chemoimmunotherapy. Bendamustine was administered at a dose of 70 mg/m(2) on days 1 and 2 combined with rituximab 375 mg/m(2) on day 0 of the first course and 500 m...    »
 
Zeitschriftentitel:
J Clin Oncol 
Jahr:
2011 
Band / Volume:
29 
Heft / Issue:
26 
Seitenangaben Beitrag:
3559-66 
Sprache:
eng 
Print-ISSN:
0732-183X 
TUM Einrichtung:
r Medizinische Statistik und Epidemiologie